Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed pre-planned stock option exercises and subsequent sales of common stock in early December 2025.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in pre-arranged transactions involving the exercise of stock options and the sale of common stock.
• On December 5, 2025, Rothblatt exercised options to acquire 4,000 shares of common stock at an exercise price of $120.26 per share.
• Immediately following, 4,000 shares were sold at weighted average prices of $482.9368 (3,000 shares) and $484.31 (1,000 shares).
• On December 8, 2025, Rothblatt again exercised options to acquire 4,000 shares of common stock at an exercise price of $120.26 per share.
• Subsequently, 4,000 shares were sold in multiple trades at weighted average prices ranging from $482.233 to $488.97.
• All transactions were conducted under a Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds shares through various family trusts and a spouse, totaling 644,393 shares.

Sentiment

Score: 6

Explanation: While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling. The significant profit realized from the option exercises reflects positively on the company's stock performance over the option's life.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a systematic approach to managing equity holdings rather than a reaction to immediate market conditions.
• The exercise price of $120.26 for the stock options is significantly lower than the sale prices (ranging from $482.233 to $488.97), indicating a substantial profit for the reporting person on these specific transactions.

Negatives

• Significant insider selling by a key executive, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake in the company.

Future Outlook

The 10b5-1 trading plan is set to continue until December 31, 2025, or until a tranche of 294,000 stock options expiring March 15, 2026, are exhausted, indicating further pre-planned transactions may occur.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.

Related Party Transactions

• Shares are held indirectly by spouse and various family trusts where the Reporting Person and/or immediate family members are beneficiaries or have shared investment power.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, but the pre-planned nature of the sales under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future. The profitable exercise of options indicates strong stock performance.
• Management: The transactions represent a personal financial planning event for the CEO, diversifying personal wealth.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2025, or until the exhaustion of 294,000 stock options expiring March 15, 2026, suggesting further pre-planned transactions may occur.

Key Dates

Recommendation

This Form 4 filing details routine, pre-planned insider transactions by the CEO under a 10b5-1 plan. While it involves significant selling, the pre-arranged nature and the substantial profit from option exercises suggest personal financial management rather than a negative signal about the company's future prospects. It does not provide new information to warrant a change in investment thesis, thus a "hold" recommendation is appropriate for existing investors. New investors should conduct further due diligence on the company's fundamentals.

Keywords

United Therapeutics, UTHR, Martine A. Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, CEO, Director, Beneficial Ownership